UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Annals of oncology, 2018-10, Vol.29, p.viii653-viii653

2018

Volltextzugriff (PDF)

Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

Annals of oncology, 2018-10, Vol.29, p.viii641-viii641

2018

Volltextzugriff (PDF)

Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)

Annals of oncology, 2018-10, Vol.29, p.viii671-viii671

2018

Volltextzugriff (PDF)

6ER-021 Evaluation of COVID mortality during hospital admission in patients receiving oncological treatment

European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A174-A174

2022

Volltextzugriff (PDF)

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

European journal of cancer (1990), 2014-11, Vol.50, p.44-45

2014

Volltextzugriff (PDF)

160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

Annals of oncology, 2021-12, Vol.32, p.S1450

2021

Volltextzugriff (PDF)

Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts)

Annals of oncology, 2017-09, Vol.28, p.v495

2017

Volltextzugriff (PDF)

Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC)

Annals of oncology, 2017-09, Vol.28, p.v465-v466

2017

Volltextzugriff (PDF)

Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs

Annals of oncology, 2017-09, Vol.28, p.v478-v479

2017

Volltextzugriff (PDF)

1806PDMultiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1490PD - A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v610-v611

2019

Volltextzugriff (PDF)

1490PDA phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v610-v611

2019

Volltextzugriff (PDF)

Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial

Annals of oncology, 2017-09, Vol.28, p.v454

2017

Volltextzugriff (PDF)

1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials

Annals of oncology, 2017-09, Vol.28, p.v570-v570

2017

Volltextzugriff (PDF)

1895PDHomology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2017-09, Vol.28, p.v462

2017

Volltextzugriff (PDF)

Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status

Annals of oncology, 2017-09, Vol.28, p.v463

2017

Volltextzugriff (PDF)

103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S753-S754

2021

Volltextzugriff (PDF)

219P Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S131-S132

2018

Volltextzugriff (PDF)

Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study

Pneumologie (Stuttgart, Germany), 2017, Vol.71 (S 01), p.S1-S125

2017

Volltextzugriff (PDF)

Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT): 219P

Journal of thoracic oncology, 2018-04, Vol.13 (4 Suppl), p.S131-S132

2018

Volltextzugriff (PDF)

Pleural effusion as a form of presentation of Waldenström's macroglobulinemia

Anales de medicina interna (Madrid, Spain : 1984), 1989-07, Vol.6 (7), p.390

1989

Volltextzugriff (PDF)

EN-2. CheckMate 017 / 057 5-year survival outcomes : NIVO vs Docetaxel in Previously Treated Advanced NSCLC

Japanese Journal of Lung Cancer, 2019-11, Vol.59 (6), p.594-594

2019

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)

6ER-021 Evaluation of COVID mortality during hospital admission in patients receiving oncological treatment

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts)

Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC)

Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs

1806PDMultiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome

1490PD - A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

1490PDA phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial

1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials

1895PDHomology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)

Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status

103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

219P Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)

Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study

Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT): 219P

Pleural effusion as a form of presentation of Waldenström's macroglobulinemia

EN-2. CheckMate 017 / 057 5-year survival outcomes : NIVO vs Docetaxel in Previously Treated Advanced NSCLC

Suchergebnisse filtern